N-benzyl-5-bromopyrazin-2-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzyl-5-bromopyrazin-2-amine
• 英文别名: N-Benzyl-5-bromopyrazin-2-amine
• 化学式: C₁₁H₁₀BrN₃
• 分子量: 264.124
• InChiKey: ASALBBMGOBKACI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-benzyl-5-bromopyrazin-2-amine 、 4-硼-L-苯丙氨酸 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium carbonate 作用下， 以 水 、 乙腈 为溶剂， 反应 0.1h， 生成 (S)-2-amino-3-(4-(5-(benzylamino)pyrazin-2-yl)phenyl)propanoic acid
  参考文献：
  名称：

  Modulation of Peripheral Serotonin Levels by Novel Tryptophan Hydroxylase Inhibitors for the Potential Treatment of Functional Gastrointestinal Disorders

  摘要：

  The discovery of a novel class of peripheral tryptophan hydroxylase (TPH) inhibitors is described. This class of TPH inhibitors exhibits excellent potency in in vitro biochemical and cell-based assays, and it selectively reduces serotonin levels in the murine intestine after oral administration without affecting levels in the brain. These TPH1 inhibitors may provide novel treatments for gastrointestinal disorders associated with dysregulation of the serotonergic system, such as chemotherapy-induced emesis and irritable bowel syndrome.

  DOI：

  10.1021/jm800338j
• 作为产物：
  描述：

  2-氨基-5-溴吡嗪 、 苯甲醛 在 trimethylamine borane 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 12.0h， 生成 N-benzyl-5-bromopyrazin-2-amine
  参考文献：
  名称：

  Modulation of Peripheral Serotonin Levels by Novel Tryptophan Hydroxylase Inhibitors for the Potential Treatment of Functional Gastrointestinal Disorders

  摘要：

  The discovery of a novel class of peripheral tryptophan hydroxylase (TPH) inhibitors is described. This class of TPH inhibitors exhibits excellent potency in in vitro biochemical and cell-based assays, and it selectively reduces serotonin levels in the murine intestine after oral administration without affecting levels in the brain. These TPH1 inhibitors may provide novel treatments for gastrointestinal disorders associated with dysregulation of the serotonergic system, such as chemotherapy-induced emesis and irritable bowel syndrome.

  DOI：

  10.1021/jm800338j

文献信息

• KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
  申请人：Icahn School of Medicine at Mount Sinai

  公开号：EP3906028A1

  公开（公告）日：2021-11-10
• [EN] KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSÉS INHIBITEURS DE KINASE, COMPOSITIONS ET MÉTHODES D'UTILISATION
  申请人：ICAHN SCHOOL MED MOUNT SINAI

  公开号：WO2020142486A1

  公开（公告）日：2020-07-09

  Disclosed are kinase inhibitor compounds having the following structure: (I), or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, R3,R4, R5, R6, N-Ar, X, Y, Z, and AA are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.
• Modulation of Peripheral Serotonin Levels by Novel Tryptophan Hydroxylase Inhibitors for the Potential Treatment of Functional Gastrointestinal Disorders
  作者：Zhi-Cai Shi、Arokiasamy Devasagayaraj、Kunjian Gu、Haihong Jin、Brett Marinelli、Lakshman Samala、Sheldon Scott、Terry Stouch、Ashok Tunoori、Ying Wang、Yi Zang、Chengmin Zhang、S. David Kimball、Alan J. Main、Weimei Sun、Qi Yang、Amr Nouraldeen、Xiang-Qing Yu、Eric Buxton、Shiv Patel、Nghi Nguyen、Jon Swaffield、David R. Powell、Alan Wilson、Qingyun Liu

  DOI：10.1021/jm800338j

  日期：2008.7

  The discovery of a novel class of peripheral tryptophan hydroxylase (TPH) inhibitors is described. This class of TPH inhibitors exhibits excellent potency in in vitro biochemical and cell-based assays, and it selectively reduces serotonin levels in the murine intestine after oral administration without affecting levels in the brain. These TPH1 inhibitors may provide novel treatments for gastrointestinal disorders associated with dysregulation of the serotonergic system, such as chemotherapy-induced emesis and irritable bowel syndrome.